Literature DB >> 32227137

Shift From Adalimumab Originator to Biosimilars in Denmark.

Thomas Bo Jensen1, Seoyoung C Kim2, Espen Jimenez-Solem1, Dorthe Bartels3, Hanne Rolighed Christensen1, Jon Trærup Andersen1.   

Abstract

Entities:  

Year:  2020        PMID： 32227137      PMCID： PMC7105946          DOI： 10.1001/jamainternmed.2020.0338

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  15 in total

1.  Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland.

Authors:  B Duggan; Amelia Smith; M Barry
Journal:  Int J Clin Pharm       Date:  2021-02-09

2.  Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.

Authors:  Soo Kyung Cho; Sun Young Jung; Hyoungyoung Kim; Yeo Jin Song; Kyungeun Lee; Yoon Kyoung Sung
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

3.  The "Square Box": Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines.

Authors:  Bernadette Cappello; Lorenzo Moja; Albert Figueras; Nicola Magrini
Journal:  Front Pharmacol       Date:  2020-09-11       Impact factor: 5.810

4.  The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.

Authors:  Meenu Wadhwa; Chris Bird; Eleanor Atkinson; Isabelle Cludts; Peter Rigsby
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

5.  Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.

Authors:  Alen Brkic; Andreas P Diamantopoulos; Espen Andre Haavardsholm; Bjørg Tilde Svanes Fevang; Lene Kristin Brekke; Liz Loli; Camilla Zettel; Erik Rødevand; Gunnstein Bakland; Pawel Mielnik; Glenn Haugeberg
Journal:  BMC Health Serv Res       Date:  2022-01-10       Impact factor: 2.655

6.  Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.

Authors:  Louise C Druedahl; Sofia Kälvemark Sporrong; Timo Minssen; Hans Hoogland; Marie Louise De Bruin; Marco van de Weert; Anna Birna Almarsdóttir
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240

7.  Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis.

Authors:  Tara Gomes; Daniel McCormack; Sophie A Kitchen; J Michael Paterson; Muhammad M Mamdani; Laurie Proulx; Lorraine Bayliss; Mina Tadrous
Journal:  CMAJ Open       Date:  2021-11-23

Review 8.  Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.

Authors:  Josef S Smolen; Roberto Caporali; Thomas Doerner; Bruno Fautrel; Fabrizio Benedetti; Burkhard Pieper; Minjun Jang
Journal:  RMD Open       Date:  2021-06

9.  The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.

Authors:  Brian Godman; Mainul Haque; Trudy Leong; Eleonora Allocati; Santosh Kumar; Salequl Islam; Jaykaran Charan; Farhana Akter; Amanj Kurdi; Carlos Vassalo; Muhammed Abu Bakar; Sagir Abdur Rahim; Nusrat Sultana; Farzana Deeba; M A Halim Khan; A B M Muksudul Alam; Iffat Jahan; Zubair Mahmood Kamal; Humaira Hasin; Shamsun Nahar; Monami Haque; Siddhartha Dutta; Jha Pallavi Abhayanand; Rimple Jeet Kaur; Godfrey Mutashambara Rwegerera; Renata Cristina Rezende Macedo do Nascimento; Isabella Piassi Dias Godói; Mohammed Irfan; Adefolarin A Amu; Patrick Matowa; Joseph Acolatse; Robert Incoom; Israel Abebrese Sefah; Jitendra Acharya; Sylvia Opanga; Lisper Wangeci Njeri; David Kimonge; Hye-Young Kwon; SeungJin Bae; Karen Koh Pek Khuan; Abdullahi Rabiu Abubakar; Ibrahim Haruna Sani; Tanveer Ahmed Khan; Shahzad Hussain; Zikria Saleem; Oliver Ombeva Malande; Thereza Piloya-Were; Rosana Gambogi; Carla Hernandez Ortiz; Luke Alutuli; Aubrey Chichonyi Kalungia; Iris Hoxha; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Ott Laius; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuoliene; Jolanta Gulbinovič; Magdalene Wladysiuk; Jakub Rutkowski; Ileana Mardare; Jurij Fürst; Stuart McTaggart; Sean MacBride-Stewart; Caridad Pontes; Corinne Zara; Eunice Twumwaa Tagoe; Rita Banzi; Janney Wale; Mihajlo Jakovljevic
Journal:  Front Public Health       Date:  2021-06-24

10.  Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.

Authors:  Kyung-Sang Yu; In-Jin Jang; Hyeong-Seok Lim; Jang Hee Hong; Min-Gul Kim; Min Kyu Park; Doo-Yeoun Cho; Min Soo Park; Jae Yong Chung; Jong-Lyul Ghim; SeungHwan Lee; Seok Kyu Yoon; In Sun Kwon; Sang Joon Lee; Sung Hyun Kim; Yun Ju Bae; Jung Bin Cha; Daniel E Furst; Edward Keystone; Jonathan Kay
Journal:  Clin Transl Sci       Date:  2021-03-02       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.